A Randomized, Open Label, Multicentre, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
This multicentre, open-label study will evaluate the safety and the efficacy of Pinatuzumab
Vedotin (DCDT2980S) in combination with rituximab (MabThera/Rituxan) or Polatuzumab Vedotin
(DCDS4501A) in combination with rituximab, as well as a combination of Polatuzumab Vedotin
with obinutuzumab in participants with relapsed or refractory follicular non-Hodgkin's
lymphoma and relapsed/refractory diffuse large B-cell lymphoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society